← Back to home

EBV+ posttransplant lymphoproliferative disease in central nervous system (EBV+ CNS PTLD)

Clinical trials for EBV+ posttransplant lymphoproliferative disease in central nervous system (EBV+ CNS PTLD) explained in plain language.

Never miss a new study

Get alerted when new EBV+ posttransplant lymphoproliferative disease in central nervous system (EBV+ CNS PTLD) trials appear

Sign up with your email to follow new studies for EBV+ posttransplant lymphoproliferative disease in central nervous system (EBV+ CNS PTLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New cell therapy targets Epstein-Barr virus in immune-compromised patients

Disease control Ongoing

This study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain lymphomas and post-transplant complications. The treatment uses specially prepared immune cells to fight the virus. The main go…

Matched conditions: EBV+ POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN CENTRAL NERVOUS SYSTEM (EBV+ CNS PTLD)

Phase 2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control

Last updated Aug 02, 2026 00:00 UTC

EBV+ posttransplant lymphoproliferative disease in central nervous system (EBV+ CNS PTLD)

Get alerted when new EBV+ posttransplant lymphoproliferative disease in central nervous system (EBV+ CNS PTLD) trials appear

New cell therapy targets Epstein-Barr virus in immune-compromised patients